drugset / Trial / NCT01357655
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to compare response rates in newly diagnosed Chronic Phase (CP) CML subjects treated with dasatinib plus BMS-833923 versus dasatinib alone.
Timeline
- Start
- 2011-09
- Primary completion
- 2016-01
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-833923 | Small molecule | — | Oral |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | Oral |